An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

Brown & Brown's fourth-quarter revenue beat analyst expectations as commissions and fees rose. The insurance company said profit fell to $210 million from $269 million a year earlier, though adjusted ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

Atomi Financial Group Inc. trimmed its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

Ballentine Partners LLC grew its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 24.3% in the 4th quarter, according to the company in its most recent filing ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.

BioLife Plasma Services LP and Takeda Pharmaceuticals USA Inc. enabled third parties to intercept the personal information of ...

Some six and a half years since its debut, Servier’s U.S. arm has made good on its oncology growth ambitions while managing to stay true to its patient-centric ethos along the way. | Some six and a ...

One of the world’s biggest global health funders will ask the private sector for a steep increase in donations as concern of ...

Upbeat about China's innovative digital business environment, Takeda continues to invest in the country as it ramps up ...